Onderneming Aastrom Biosciences Inc Nasdaq
Aandelen
US00253U4040
Farmaceutische producten
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
MACI
83,4
%
| 132 | 80,3 % | 165 | 83,4 % | +24,88% |
Epicel
16,0
%
| 32 | 19,3 % | 32 | 16,0 % | -0,49% |
NexoBrid
0,6
%
| 1 | 0,4 % | 1 | 0,6 % | +71,21% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 164 | 100,0 % | 198 | 100,0 % | +20,17% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 60 | 01-03-13 | |
Joseph Mara
DFI | Director of Finance/CFO | 49 | 25-01-21 |
Michael Halpin
COO | Chief Operating Officer | 62 | 10-04-17 |
Jonathan Hopper
CTO | Chief Tech/Sci/R&D Officer | 61 | 20-08-18 |
Eric Burns
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | - | 01-01-11 | |
Jonathan Siegal
AUD | Comptroller/Controller/Auditor | 45 | 01-09-21 |
Corporate Officer/Principal | - | 07-09-21 | |
Sean Flynn
LAW | General Counsel | 50 | 06-11-19 |
Roland DeAngelis
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Wotton
BRD | Director/Board Member | 63 | 06-01-15 |
Kevin McLaughlin
BRD | Director/Board Member | 67 | 06-01-15 |
Robert Zerbe
CHM | Chairman | 73 | 16-01-06 |
Chief Executive Officer | 60 | 01-03-13 | |
Alan Rubino
BRD | Director/Board Member | 69 | 28-09-05 |
Steven Gilman
BRD | Director/Board Member | 71 | 06-01-15 |
Heidi Hagen
BRD | Director/Board Member | 55 | 23-08-13 |
Lisa Wright
BRD | Director/Board Member | 49 | 01-06-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 48 380 458 | 47 949 467 ( 99,11 %) | 0 | 99,11 % |
Bedrijfsgegevens
Sector
Verkoop per activiteit
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,45% | 40,51 mld. | |
-15,94% | 31,67 mld. | |
+52,66% | 24,62 mld. | |
-14,50% | 15,65 mld. | |
-14,38% | 12,07 mld. | |
-9,12% | 11,97 mld. | |
-42,56% | 11,61 mld. | |
+4,87% | 8,81 mld. | |
-4,33% | 8,5 mld. |